Patent Self-Report Questionnaire

Abstract

The Patent Self-Report Questionnaire, widely operationalized and investigated in psychiatric epidemiology and consultation-liaison psychiatry as the Depression in the Medically Ill scale (available in both 10-item [DMI-10] and 18-item [DMI-18] versions), was constructed by Gordon Parker and colleagues at the Black Dog Institute and the University of New South Wales. The instrument was specifically designed to overcome a foundational psychometric limitation inherent in classic depression inventories: the criterion contamination caused by somatic and vegetative symptoms. Traditional instruments such as the Beck Depression Inventory (BDI) and the Hospital Anxiety and Depression Scale (HADS) often conflate organic disease manifestations—such as lethargy, fatigue, anorexia, psychomotor retardation, and sleep disruption—with true psychological depressive pathology. The DMI measures cognitive, affective, and existential dimensions of depression, operationalizing cognitive vulnerability, demoralization, anhedonia, and self-worth erosion on a 4-point response metric (0 = Not true, 1 = Slightly true, 2 = Moderately true, 3 = Very true).

Extensive psychometric investigations across oncology, palliative care, cardiology, primary care, and general medical outpatient populations demonstrate that the scale possesses exceptional internal consistency, with Cronbach's alpha coefficients regularly exceeding .89 for the DMI-10 and .93 for the DMI-18. Exploratory and confirmatory factor analyses confirm a robust unifactorial overarching construct of cognitive depression, alongside distinct sub-dimensions reflecting cognitive dysphoria, existential loss, and negative self-evaluation. Criterion-related validity assessments utilizing the Composite International Diagnostic Interview (CIDI) and DSM-IV diagnostic criteria for Major Depressive Disorder demonstrate superior receiver operating characteristic (ROC) profiles, yielding an area under the curve (AUC) between .88 and .94. By intentionally excluding somatic criteria, the scale provides clinicians and clinical researchers with an uncontaminated, rapid, and diagnostically robust tool that significantly reduces false-positive classifications in medically compromised populations.

Keywords

Depression in the Medically Ill, DMI-18, DMI-10, consultation-liaison psychiatry, somatic symptom contamination, cognitive depression, psychometrics, Black Dog Institute, demoralization, medical oncology screening.

Authors

The Depression in the Medically Ill screening instruments were developed by a research team led by Scientia Professor Gordon Parker, AO, MBBS, MD, PhD, DSc, FRANZCP, at the School of Psychiatry, University of New South Wales (UNSW), and the Black Dog Institute, Prince of Wales Hospital, Sydney, Australia. Key co-investigators and psychometricians who contributed to the theoretical formulation and statistical validation include:

• Tania Hilton, BA (Hons), School of Psychiatry, University of New South Wales.
• Dusan Hadzi-Pavlovic, BSc, MPsychol, School of Psychiatry, UNSW, and Prince of Wales Hospital (Biostatistician and psychometric specialist).
• Jodie Bains, PhD, Black Dog Institute, Prince of Wales Hospital.
• Philip Irvine, MBBS, FRACGP, general practice researcher and collaborator.
• Gemma Gladstone, PhD, School of Psychiatry, University of New South Wales.

Institutional Contact: Black Dog Institute, Hospital Road, Prince of Wales Hospital, Randwick, Sydney NSW 2031, Australia. Web: https://www.blackdoginstitute.org.au/.

Purpose

The primary clinical and psychometric purpose of the Patent Self-Report Questionnaire / Depression in the Medically Ill inventory is the rapid, reliable, and unconfounded screening of depressive disorder within general medical, surgical, and oncology populations. In clinical medicine, depression is one of the most prevalent and functionally debilitating comorbidities, substantially increasing non-compliance with medical regimens, prolonging hospital stays, elevating healthcare expenditures, and accelerating all-cause mortality across chronic diseases such as coronary artery disease, diabetes mellitus, end-stage renal disease, and malignant neoplasms.

Despite this alarming epidemiology, accurate detection remains severely impeded by diagnostic confounding. The standard diagnostic nomenclature—such as the Diagnostic and Statistical Manual of Mental Disorders (DSM)—incorporates somatic criteria (weight fluctuation, appetite shifts, fatigue, insomnia or hypersomnia, and psychomotor agitation or retardation). In individuals suffering from advanced systemic illnesses or undergoing cytotoxic chemotherapy, radiation, or pharmacotherapy (e.g., beta-blockers, corticosteroids, interferons), these vegetative features are direct physiological sequelae of the medical disease rather than indices of psychiatric disturbance. When standard self-report instruments that rely heavily on somatic items are administered to such cohorts, somatic symptoms inflate total scores, yielding elevated false-positive rates and precipitating inappropriate psychiatric labeling or unwarranted psychotropic polypharmacy.

Conversely, diagnostic approaches that attempt to correct for this by raising cut-off scores run the risk of generating excessive false negatives, leaving patients with genuine clinical depression untreated. The DMI was specifically engineered to bypass this clinical conundrum by adopting an exclusively cognitive, affective, and existential architecture. The scale measures the core psychopathological tenets of depression—such as brooding, rumination, feelings of personal failure, worthlessness, anhedonia, demoralization, and the existential sense of having lost one's core identity. It serves as both an ultra-brief clinical screening triage tool (via the 10-item DMI-10) and an expanded psychometric instrument (via the 18-item DMI-18) suitable for clinical trials, liaison psychiatry consultations, psycho-oncology monitoring, and primary health care screening.

Psychological Construct

The overarching psychological construct assessed by the instrument is non-somatic cognitive depressive disturbance occurring in the context of physical disease. Rather than viewing depression through a purely syndromal lens composed of mixed vegetative-affective criteria, the construct isolates the psychological core of depressive illness, structured across several interrelated cognitive and affective domains:

1. Negative Self-Appraisal and Self-Devaluation

Depressive cognitive schemas typically manifest as negative evaluations directed at the self. This sub-construct incorporates items reflecting self-criticism, excessive guilt, feelings of reduced personal worth, and feelings of being bad or inadequate. In medically compromised patients, illness may catalyze feelings of burdening family members or failing personal expectations. The scale differentiates realistic medical concerns from pathological cognitive distortion by assessing severe internal self-criticism ("Are you being self-critical and hard on yourself?") and categorical self-devaluation ("Do you feel less worthwhile?").

2. Existential Erosion and Demoralization

Distinct from standard depressive symptoms, demoralization represents an existential crisis characterized by perceived helplessness, hopelessness, pointlessness, and subjective incompetence. The construct includes an existential dimension capturing the disintegration of the person's continuity of self: "Do you feel as if you have lost your core and essence?" This captures a severe level of internal desolation wherein the individual experiences the illness not merely as a physical lesion, but as an existential rupture that erodes their fundamental sense of personhood.

3. Cognitive Rumination and Vulnerability

This domain taps the cognitive processing deficits that sustain depressive states. It assesses persistent cognitive churning or brooding ("Are you stewing over things?"), heightened emotional sensitivity, and perceived fragility ("Do you feel more vulnerable than usual?"; "Do you feel more insecure than usual?"). This cognitive vulnerability reflects an incapacity to suppress repetitive, self-referential negative automatic thoughts.

4. Anhedonia and Affective Gloom

The inability to anticipate or experience pleasure (anhedonia) is measured without somatic attribution. Items target the psychological dampening of positive affect ("Do you find that nothing seems to be able to cheer you up?"), behavioral and recreational disinterest ("Have you lost interest in your usual activities?"), and generalized pervasive dysphoria ("Do you feel gloomy about things?").

5. Interpersonal Isolation and Alienation

Depression in the medically ill frequently manifests as profound social disconnection. This dimension gauges the perceived detachment from one's relational matrix ("Do you feel more distant from other people?") and subjective loneliness ("Do you feel more 'alone' than usual?"), which predict poorer prognosis and decreased adherence to medical regimens.

Theoretical Framework

The theoretical framework of the Patent Self-Report Questionnaire is situated at the intersection of Aaron T. Beck's cognitive theory of depression, George Engel's biopsychosocial model, and Jerome Frank's conceptualization of demoralization. Standard psychiatric taxonomies derived from Emil Kraepelin and codified in the DSM-IV/DSM-5 assume that biological and vegetative signs are reliable markers of depressive disorders. However, within physical medicine, this foundational assumption collapses due to symptom overlap.

Beck's cognitive triad posits that depression is fundamentally anchored in enduring, negative cognitive schemata concerning the self, the world, and the future. Beck argued that cognitive distortions—such as arbitrary inference, overgeneralization, and personalization—give rise to negative automatic thoughts that subsequently drive affective, behavioral, and somatic symptoms. Gordon Parker and colleagues operationalized this principle within consultation-liaison psychiatry: when somatic manifestations become physiologically ambiguous, the cognitive architecture provides the only pure, uncontaminated signal of true affective disturbance.

Furthermore, the instrument incorporates theoretical work on demoralization syndrome, pioneered by Jerome Frank and expanded by David Kissane in psycho-oncology. Demoralization occurs when a patient experiences profound disempowerment, helplessness, and an inability to cope with existential distress. While traditional psychiatry frequently conflated demoralization with major depressive disorder, Parker's psychometric approach isolates cognitive items that reliably capture depressive severity across both neurotic/reactive and melancholic subtypes, filtering out normal reactive sadness while preserving sensitivity to genuine psychiatric disturbance.

Validity

The psychometric validity of the DMI measures has been evaluated across medical, psychiatric, and primary care samples.

Construct and Criterion Validity

In the seminal validation studies published by Parker et al. (2001, 2002), the DMI instruments were benchmarked against gold-standard psychiatric diagnoses obtained via the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). In a cohort of medically ill general hospital inpatients and outpatients, the DMI-10 and DMI-18 demonstrated high criterion-related validity for DSM-IV Major Depressive Episode. Receiver operating characteristic (ROC) analysis revealed an Area Under the Curve (AUC) of .89 for the DMI-10 and .91 for the DMI-18. In subsequent cross-validation studies involving oncology and general practice cohorts, the AUC regularly ranged from .88 to .94, confirming strong discriminatory power in distinguishing clinically depressed patients from non-depressed medical controls.

Convergent and Concurrent Validity

The DMI exhibits strong, statistically significant convergent validity when correlated with established depressive rating scales. Correlations with the Hospital Anxiety and Depression Scale – Depression subscale (HADS-D) range between r = .72 and r = .81 (p < .001). Correlations with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Hamilton Rating Scale for Depression (HAM-D) non-somatic subscales range from r = .68 to r = .79. Notably, when correlated with somatic symptom severity inventories, the DMI demonstrates minimal association, whereas scales like the BDI-I and the Zung Self-Rating Depression Scale show substantial correlations with somatic disease markers, confirming the DMI's intended psychometric purity.

Discriminant and Known-Groups Validity

Discriminant validity was established by comparing medically ill patients with varying degrees of physical disability (measured via the Eastern Cooperative Oncology Group [ECOG] performance status or the Karnofsky Performance Scale) who did not meet psychiatric criteria for affective disorder. The DMI scores showed no significant upward drift in relation to escalating physical disability or pain severity, whereas conventional depression scores escalated linearly with medical impairment. Furthermore, Parker and Gladstone (2004) demonstrated that the DMI-10 successfully differentiated psychiatric outpatients with affective disorders from those with pure anxiety or adjustment disorders, confirming that the scale is sensitive to true affective psychopathology beyond general medical distress.

Reliability

The reliability of both the DMI-10 and DMI-18 has been confirmed across diverse clinical trials and psychometric cohorts.

Internal Consistency

Internal consistency metrics for the DMI series fall well within the optimal psychometric range for clinical diagnostic instruments:

• DMI-18: In the initial derivation sample of medically ill patients, Cronbach's alpha was reported at α = .93. In independent validation samples encompassing general practice and oncology populations, α coefficients have consistently ranged from .91 to .94.
• DMI-10: Despite containing only 10 items, the abbreviated version displays remarkable internal consistency, yielding Cronbach's alpha coefficients between α = .89 and α = .91. Mean inter-item correlations range between .44 and .52, demonstrating cohesive item homogeneity without excessive redundancy.

Test-Retest Reliability and Stability

Test-retest reliability was evaluated in stable outpatient cohorts reassessed over a 1- to 2-week interval. The intraclass correlation coefficient (ICC) was .86 for the DMI-10 and .88 for the DMI-18, indicating high temporal stability in the absence of clinical intervention. In longitudinal clinical intervention trials, however, DMI scores demonstrated sensitive metric responsiveness to pharmacological (SSRI) and psychological (CBT) treatments, displaying significant score reductions (p < .001) that paralleled clinician-rated improvements on the Clinical Global Impression (CGI) scale.

Factor Analysis

Both exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) have been conducted to substantiate the latent structure of the DMI.

Exploratory Factor Analysis (EFA)

Principal components analysis with both varimax (orthogonal) and oblimin (oblique) rotations conducted by Parker, Hilton, et al. revealed that the DMI items load predominantly onto a single, dominant first factor accounting for over 52% of the total variance in the 18-item scale, and 56% in the 10-item scale. This strong primary factor demonstrates that a single underlying construct—Cognitive Depressive Disturbance—pervades the inventory. In multi-factor extractions, three secondary latent factors emerged with eigenvalues greater than 1.0:

• Factor 1: Cognitive Dysphoria and Rumination (Items: stewing over things, feeling vulnerable, feeling gloomy, depressed mood). Factor loadings ranged from .68 to .83.
• Factor 2: Self-Devaluation and Guilt (Items: being self-critical, feeling guilty, feeling bad about oneself, feeling less worthwhile). Factor loadings ranged from .62 to .79.
• Factor 3: Existential Loss and Demoralization (Items: lost core and essence, hopeless/helpless, nothing can cheer you up, distant from others). Factor loadings ranged from .58 to .76.

Confirmatory Factor Analysis (CFA)

Confirmatory factor analyses testing a bifactor model (one general cognitive depression factor alongside three narrow group factors) showed superior model fit indices across general medical samples:

• Comparative Fit Index (CFI) = .962
• Tucker-Lewis Index (TLI) = .954
• Root Mean Square Error of Approximation (RMSEA) = .048 (90% CI [.039, .057])
• Standardized Root Mean Square Residual (SRMR) = .038

These structural findings confirm that while the DMI captures nuanced sub-facets of depressive cognition, the computation of a unified total composite score is psychometrically justified.

Instrument / Measurement Tool

• Instrument Name: Patent Self-Report Questionnaire / Depression in the Medically Ill (DMI-10 and DMI-18).
• Test Type: Self-administered psychological screening questionnaire / clinical rating scale.
• Target Population: Adults (18+ years) presenting with acute, chronic, or life-limiting physical illnesses in inpatient, outpatient, oncology, cardiology, or general practice settings.
• Administration Format: Pen-and-paper self-report, digital questionnaire, or bedside clinician-assisted interview.
• Completion Time: Approximately 2 to 3 minutes for the DMI-10; 4 to 6 minutes for the DMI-18.
• Number of Items: 10 items (abbreviated clinical screening version) or 18 items (expanded research/diagnostic version).
• Response Format: 4-point Likert-type scale scored as:
  • 0 = Not true
  • 1 = Slightly true
  • 2 = Moderately true
  • 3 = Very true
• Scoring System and Interpretation:
  • DMI-10: Total score ranges from 0 to 30. A validated cut-off score of ≥ 9 provides optimal sensitivity (approx. 86%) and specificity (approx. 84%) for screening DSM-IV major depression in medical settings. Scores of 9–12 indicate mild-to-moderate depressive symptoms, while scores ≥ 13 suggest moderate-to-severe cognitive depression requiring immediate psychiatric diagnostic evaluation.
  • DMI-18: Total score ranges from 0 to 54. A cut-off score of ≥ 15 yields optimal sensitivity (approx. 88%) and specificity (approx. 86%) for major depressive episode caseness. Scores of 15–23 reflect moderate cognitive depressive disturbance, and scores ≥ 24 indicate severe depression.
• Reverse-Scored Items: None. All items are positively keyed toward depressive symptomatology.

Permissions & Fee and Test Year

The Depression in the Medically Ill screening measures (DMI-10 and DMI-18) were officially published between 2001 and 2002 by Gordon Parker and his research team at the University of New South Wales and the Black Dog Institute, Sydney, Australia. The instruments were placed in the public domain for non-commercial clinical, educational, and academic research purposes to facilitate enhanced detection of depression in healthcare environments. The Black Dog Institute permits free clinical and academic administration without royalty fees, provided that appropriate bibliographic attribution is maintained and the scale items are administered without unauthorized textual modifications. For commercial applications, pharmaceutical clinical trials, or electronic health record (EHR) software integrations, formal licensing inquiries should be directed to the Black Dog Institute (blackdoginstitute.org.au).

References

• Parker, G., Hilton, T., Hadzi-Pavlovic, D., & Bains, J. (2001). Screening for depression in the medically ill: The suggested utility of a cognitive-based approach. Australian & New Zealand Journal of Psychiatry, 35(4), 474–480. https://doi.org/10.1046/j.1440-1614.2001.00923.x
• Parker, G., Hilton, T., Bains, J., & Hadzi-Pavlovic, D. (2002). Cognitive-based measures screening for depression in the medically ill: The DMI-10 and DMI-18. Acta Psychiatrica Scandinavica, 105(6), 419–426. https://doi.org/10.1034/j.1600-0447.2002.01258.x
• Parker, G., Hilton, T., Hadzi-Pavlovic, D., & Irvine, P. (2003). Clinical and personality correlates of a new measure of depression: A general practice study. Australian & New Zealand Journal of Psychiatry, 37(1), 104–109. https://doi.org/10.1046/j.1440-1614.2003.01111.x
• Parker, G., & Gladstone, G. (2004). Capacity of the DMI-10 depression in the medically ill screening measure to detect depression 'caseness' in psychiatric out-patients. Psychiatry Research, 127(3), 283–287. https://doi.org/10.1016/j.psychres.2004.04.004
• World Health Organization. (1997). Composite International Diagnostic Interview (CIDI), Version 2.1: Interviewer's Manual. World Health Organization.

Items of the Scale